A group including Celgene, the Duke of Bedford, Disney family members and others complete a new round of investment in Dragonfly, to accelerate development of its novel Natural Killer cell-based immunotherapies.
CAMBRIDGE, Mass., May 15, 2017 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Celgene Switzerland LLC, an affiliate of Celgene Corporation, a leading global biopharmaceutical company, and a number of family office investors including Disney family members and the Duke of Bedford, have completed a new round of investment in Dragonfly.
"This investment by Celgene, Disney family members and the Duke of Bedford, reflects their confidence in our mission to revolutionize cancer treatment by inventing therapies that harness the body's immune system for vastly improved patient outcomes," said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. "We appreciate the demonstrated confidence in the future of Dragonfly, and are eager to accelerate our work to develop potential new immuno-oncology treatment options for patients."
About Dragonfly Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer.
Our scientific founders are major figures in cancer biology and immunology and launched Dragonfly to harness the power of the innate immune system to provide breakthrough cancer treatments for patients.